找回密碼
 To register

QQ登錄

只需一步,快速開始

掃一掃,訪問微社區(qū)

打印 上一主題 下一主題

Titlebook: Genitourinary Cancers; Siamak Daneshmand,Kevin G. Chan Book 2018 Springer International Publishing AG, part of Springer Nature 2018 Genito

[復(fù)制鏈接]
樓主: FERAL
11#
發(fā)表于 2025-3-23 10:16:39 | 只看該作者
U. Wollina,M. Gebhardt,D. Lange are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.
12#
發(fā)表于 2025-3-23 15:11:26 | 只看該作者
13#
發(fā)表于 2025-3-23 20:10:09 | 只看該作者
Molecular Prognostication in Bladder Cancer, are capable of reproducibly predicting patient outcomes. Future management of bladder cancer will likely incorporate such prognostic molecular models for risk stratification and treatment personalization.
14#
發(fā)表于 2025-3-24 00:38:46 | 只看該作者
15#
發(fā)表于 2025-3-24 05:46:21 | 只看該作者
Carmen I. Hernandez Lara BS, PhDr greater certainty for cancer control, but at the risk of significant urinary and/or sexual morbidity. Conversely, AS preserves genitourinary function and quality of life in exchange for burdensome surveillance and the psychological impact of living with cancer.
16#
發(fā)表于 2025-3-24 09:52:01 | 只看該作者
Miscellaneous Drug-related Adverse Effects,ous blood-based analytes, provide a method of patient evaluation with potential applications in virtually all disease states. In this review, we will describe current approaches with a particular focus on demonstrated clinical utility in the evaluation and management of prostate cancer.
17#
發(fā)表于 2025-3-24 13:52:54 | 只看該作者
18#
發(fā)表于 2025-3-24 18:08:11 | 只看該作者
19#
發(fā)表于 2025-3-24 22:18:16 | 只看該作者
20#
發(fā)表于 2025-3-25 00:00:11 | 只看該作者
Advances in the Treatment of Metastatic Renal Cell Carcinoma,ad resurgence with the FDA approval of nivolumab with ipilimumab. In the current chapter, we attempt to contextualize available frontline therapies for metastatic renal cell carcinoma with a focus on the CABOSUN and CheckMate 214 clinical trials.
 關(guān)于派博傳思  派博傳思旗下網(wǎng)站  友情鏈接
派博傳思介紹 公司地理位置 論文服務(wù)流程 影響因子官網(wǎng) 吾愛論文網(wǎng) 大講堂 北京大學(xué) Oxford Uni. Harvard Uni.
發(fā)展歷史沿革 期刊點(diǎn)評(píng) 投稿經(jīng)驗(yàn)總結(jié) SCIENCEGARD IMPACTFACTOR 派博系數(shù) 清華大學(xué) Yale Uni. Stanford Uni.
QQ|Archiver|手機(jī)版|小黑屋| 派博傳思國(guó)際 ( 京公網(wǎng)安備110108008328) GMT+8, 2025-10-8 02:53
Copyright © 2001-2015 派博傳思   京公網(wǎng)安備110108008328 版權(quán)所有 All rights reserved
快速回復(fù) 返回頂部 返回列表
陆川县| 镇宁| 丹凤县| 丰原市| 齐齐哈尔市| 霍山县| 鄂尔多斯市| 荆门市| 芒康县| 大兴区| 剑河县| 离岛区| 河北省| 余姚市| 界首市| 阿拉善盟| 辉县市| 南昌县| 福州市| 舒兰市| 滁州市| 绥芬河市| 岱山县| 新乐市| 汕头市| 双城市| 马边| 都江堰市| 通山县| 呼伦贝尔市| 福贡县| 荣昌县| 丹江口市| 西青区| 马鞍山市| 阳山县| 修文县| 高台县| 灵璧县| 崇左市| 咸阳市|